Today BioGaia has signed an agreement with Ferozsons Laboratories Limited, for
the exclusive rights to sell BioGaia’s probiotic drops and tablets in Pakistan.
The products will be sold under the BioGaia brand and launch is planned to 2013.
Ferozsons Laboratories Limited (http://www.ferozsons-labs.com/) is one of
Pakistan's leading pharmaceutical companies. Several of the company’s brands are
market leaders in the fields of gastroenterology, cardiology and
oncology. Ferozsons Laboratories Limited is focused on medical marketing and has
a large medical field force. The company has been listed on Pakistan’s three
Stock Exchanges since 1960.

Both the BioGaia ProTectis baby drops and the BioGaia ProTectis tablets contain
BioGaia’s patented and well researched probiotic strain Lactobacillus reuteri
Protectis. Today the drops are available in 52 countries and the tablets in 46
countries.

“We are pleased with the agreement with Ferozsons Laboratories Limited. As
Pakistan has a population of 187 million people – the world’s sixth most
populous – and in addition a large proportion is children, the potential for our
probiotic products should be good”, says Peter Rothschild, Chief Executive
Officer, BioGaia.

Latest press releases from BioGaia
2012-09-17              Lactobacillus reuteri Protectis shown to reduce colic in
infants
2012-09-07              BioGaia’s probiotic prevented necrotizing enterocolitis
in high risk premature infants
2012-08-21              BioGaia AB Interim report 1 January-30 June 2012

BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 12 October 2012, 10:30
am CET.
For additional information please contact

Peter Rothschild, Chief Executive Officer, telephone: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com